Triptans have long been the mainstay of acute treatment of migraine; however, in 2020, three novel oral nontriptan brands—Eli Lilly’s Reyvow, AbbVie / Allergan’s Ubrelvy, and Biohaven’s Nurtec ODT—entered the U.S. market. These therapies offer clinically distinct alternatives to triptans, particularly for patients who cannot tolerate, are contraindicated to, or do not adequately respond to triptans. Additional oral nontriptans are set to enter the market in the coming years and will offer further choice. In this report, we leverage national patient-level claims data to assess the uptake and performance of newer brands versus those of the standard of care. Understanding the treatment paradigms and patient flow will provide needed context for developers entering a heavily generic and increasingly saturated market.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Eli Lilly, AbbVie / Allergan, Biohaven Pharmaceuticals, Upsher-Smith, Currax Pharmaceuticals
Key drugs: Reyvow, Ubrelvy, Nurtec ODT, Onzetra Xsail, Tosymra, Zembrace SymTouch, generic triptans, ergot derivatives, Cambia
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, and expanded analyses.